AltruBio

Series-B
altrubio.com Biotech & Healthcare San Francisco, United States 11–50 employees
Total Funding $288M
Latest Round $225M Series-B
Last Announced May 21, 2024
Investors 8 Backers
Decision Makers 6 Available

About AltruBio

AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters San Francisco, United States
Team Size 11–50 employees
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website altrubio.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Company Profile

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $225,000,000 · Series-B

    Backed by Biotechnology Value Fund

  2. Capital Raise

    Raised $63,000,000 · Series-A

    Backed by aMoon Fund

Investors & Backers

8
aMoon Fund
Lead
Biotechnology Value Fund
Lead
Blackstone
CAM Capital
Cormorant Asset Management
Delos Capital
RA Capital Management
Soleus Capital

Funding History

2 Rounds
Series-B equity · May 21, 2024

Round backers: Biotechnology Value Fund

Series-A equity · Apr 15, 2021

Round backers: aMoon Fund

$63,000,000 altrubio.com

Founders & Leadership

2

Jeroen Grasman

CFO

Work email & phone locked Unlock →

Shih-Yao Lin

Vice President

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts